Federal Grant
Federal Grant funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
RFA-DA-26-056: Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
NIDA's RFA-DA-26-056 funds R21 projects that use existing social, behavioral, administrative, and neuroimaging data to study substance use, related disorders, prevention, HIV, and service use without new data collection.
RFA-DK-26-315: Advancing Research on Digital Health Technology for Type 2 Diabetes (R01)
NIH RFA-DK-26-315 is a clinical-trial R01 opportunity for U.S. institutions to test digital health approaches to improve type 2 diabetes management, with submission cycles in 2026 and 2027 and a strict non-responsiveness rule against tool-building and T1D-only projects.
RFA-DK-27-126: Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning Community (KUH-FAMILY) (U24 Clinical Trials Not Allowed)
NIH is seeking one RFA-DK-27-126 cooperative agreement to establish a coordinating center that builds a sustained translational learning ecosystem for kidney, urologic, and hematologic disease research through shared clinical and data infrastructure.
RFA-ES-25-002: Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional)
NIH's RFA-ES-25-002 invites U.S. institutions to build environmental health sciences core center infrastructure (P30), with recurring due dates in 2026 and 2027 for a long-cycle, multi-disciplinary research program.
RFA-HD-27-007: Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research
This NIH RFA requests grant applications that use existing HIV/AIDS archives and biospecimen repositories to generate high-impact research on maternal and pediatric HIV outcomes.
RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)
NIH’s NHLBI Emerging Investigator Award (R35, clinical trial optional) supports established HLBS investigators with at least two NHLBI R01-equivalent grants for up to seven years of flexible, program-level funding, with the next listed due date on 19 February 2027.
RFA-HL-26-017: NIH Catalyze Product Definition for Small Molecules and Biologics (R61/R33)
NIH's RFA-HL-26-017 supports early-stage translational projects that generate and validate therapeutic candidates for HLBS diseases through a phased R61/R33 development pathway.
RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing, Diagnostics, and Assay Development (R61/R33)
NIH NHLBI Catalyze Product Definition NOFO for phased R61/R33 support of early-stage device, diagnostic, and assay development (clinical trials not allowed), with ongoing application rounds in 2026 and 2027.
RFA-HL-27-004: Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)
NIH’s NHLBI RFA-HL-27-004 is a limited-competition R03 small grant opportunity to help current and recently completed NHLBI K01/K08/K23/K25 awardees advance toward independent funding through a short, NIH-funded pilot- to proof-of-concept scale project.
RFA-NS-25-023: HEAL Initiative Studies to Enable Analgesic Discovery (R61/R33, Clinical Trial Not Allowed)
NIH HEAL funds preclinical translational work to build stronger evidence for non-addictive analgesic discovery through a two-stage R61/R33 mechanism with no clinical trials and strict peer-review criteria.